Home > Boards > US Listed > Medical - Drugs > Oramed Pharmaceuticals (ORMP)

Company Description

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
trendmkr Member Profile
 
Followed By 12
Posts 911
Boards Moderated 0
Alias Born 05/29/15
160x600 placeholder
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/11/2019 4:53:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/6/2019 6:02:01 AM
Oramed Appoints Dr. Arie Mayer to Board of Directors PR Newswire (US) - 12/5/2019 9:12:00 AM
Oramed to Present a Scientific Poster at International Diabetes Federation Congress PR Newswire (US) - 12/2/2019 8:25:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 11/27/2019 4:28:28 PM
Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology PR Newswire (US) - 11/21/2019 8:27:00 AM
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event PR Newswire (US) - 11/19/2019 8:55:00 AM
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th PR Newswire (US) - 11/14/2019 7:28:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:04:56 AM
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes PR Newswire (US) - 11/12/2019 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/23/2019 4:36:39 PM
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire (US) - 9/18/2019 8:38:00 AM
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801 PR Newswire (US) - 9/17/2019 8:40:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:09:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:08:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:48 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/16/2019 6:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:06:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:18:02 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/5/2019 4:49:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/5/2019 4:42:36 PM
Oramed to Present at Three Upcoming Conferences PR Newswire (US) - 9/3/2019 8:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/21/2019 5:28:25 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/6/2019 1:29:52 PM
trendmkr   Tuesday, 12/27/16 11:59:40 AM
Re: None
Post # of 525 
Company Description

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist